Encouraging responses with bevacizumab in recurrent low-grade serous ovarian cancer.

e15503 Background: Low-grade serous ovarian carcinomas (LGSOC) represent approximately 10% of serous ovarian cancers, but are notoriously resistant to conventional chemotherapeutic agents. The objective of this study was to examine the clinical efficacy of bevacizumab with concurrent chemotherapy in patients with recurrent LGSOC. Methods: A retrospective review of patients with recurrent LGSOC treated with bevacizumab between 2005 and 2008 was performed. All cases were reviewed by a gynecologic pathologist to confirm low-grade serous histology. Demographic and clinical variables were abstracted from the medical record. Response was determined using the modified RECIST. Results: We identified 17 patients with LGSOC treated with bevacizumab. All patients had recurrent disease and were previously treated with cytotoxic chemotherapy and/or hormonal agents with a median of 4 regimens (range 1-11). Bevacizumab was given in combination with other agents including taxane and platinum (n = 4), taxane alone (n = 3)...